fashion -WSS

fashion

author：comprehensive 2025-08-30 14:29:28 - browse：4

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Beam Therapeutics to lay off 20% of its staff, re

hotspot

WSS

STAT Summit: GSK CEO on pharma giant's new direction

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

A solution to the after

Obesity drugs seen as possible treatment for liver disease MASH

Obesity drugs seen as possible treatment for liver disease MASH

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

focus

fashion

focus

Anesthesiologist group: stop taking Ozempic before surgery

A solution to the after

Virginia high school admissions case could be legal follow

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Jerome Adams on the need for new antivirals for Covid

Why health workers in Gaza are injured or die at high rates

As demand for Covid shots wanes, Moderna seeks its next success

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

He's a Nobel laureate. Critics say he was misleading on Covid

focus

Lawmakers consider Medicare pay reforms for doctors

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

STAT readers on older presidents, polypills, Medicare, and more

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

With competition flaring, obesity drug hits goal in liver disease study

FDA gives detailed accounting of AI

explore

hotspot

hotspot

hotspot